Cellectar Biosciences Inc (NASDAQ:CLRB) Sellers Reduced By 0.77% Their Shorts

April 16, 2018 - By Samuel McNeil

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Corporate Logo

Change of 0.77% for Cellectar Biosciences Inc (NASDAQ:CLRB)’s shares shorted was recorded. FINRA published shares shorted of CLRB’s total 1.08M shares. That’s 0.77% down from 1.09 million shares. Cellectar Biosciences Inc (NASDAQ:CLRB) has 353,700 shares average volume. It’ll cost 3 days for CLRB to recover its former position.

CLRB reached $1.27 on during the last trading session after $0.02 change.Cellectar Biosciences, Inc. has volume of 55,907 shares. Since April 16, 2017 CLRB has declined 51.67% and is downtrending. The stock underperformed the S&P 500 by 63.22%.

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates for the treatment and imaging of cancer.The company has $22.10 million market cap. The firm offers CLR 131, a PDC cytotoxic radioisotope product candidate, which is in Phase I clinical study for the treatment of relapse or refractory multiple myeloma, as well as in Phase II clinical study for the treatment of B-cell malignancies; and CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease.Last it reported negative earnings. It also provides CLR 124, a cancer-targeting positron emission tomography imaging PDC for the selective detection of tumors and metastases in a range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.